Meet our SPARK Fellows
Introducing Cohort 8
Karin Payne, PhD
A Regenerative Biomaterial Therapeutic to Treat Osteoarthritis
Email Address:karin.payne@cuanschutz.edu
A Regenerative Biomaterial Therapeutic to Treat Osteoarthritis
Osteoarthritis (OA) affects millions globally, causing pain, stiffness, and disability, with significant economic costs. Current treatments focus on pain management, lacking curative options. We are developing novel biomaterials that mimic cartilage and bone to support regeneration, aiming to reverse OA through minimally invasive arthroscopic therapy. Our project will help define the target product profile, pre-clinical studies for FDA approval, and develop an insurance reimbursement strategy.
Learn more about Dr. PayneCohort 7
Cohort 6
Karin Payne, PhD
A Regenerative Biomaterial Therapeutic to Treat Osteoarthritis
Email Address:karin.payne@cuanschutz.edu
A Regenerative Biomaterial Therapeutic to Treat Osteoarthritis
Osteoarthritis (OA) affects millions globally, causing pain, stiffness, and disability, with significant economic costs. Current treatments focus on pain management, lacking curative options. We are developing novel biomaterials that mimic cartilage and bone to support regeneration, aiming to reverse OA through minimally invasive arthroscopic therapy. Our project will help define the target product profile, pre-clinical studies for FDA approval, and develop an insurance reimbursement strategy.
Learn more about Dr. PayneCohort 5
Karin Payne, PhD
A Regenerative Biomaterial Therapeutic to Treat Osteoarthritis
Email Address:karin.payne@cuanschutz.edu
A Regenerative Biomaterial Therapeutic to Treat Osteoarthritis
Osteoarthritis (OA) affects millions globally, causing pain, stiffness, and disability, with significant economic costs. Current treatments focus on pain management, lacking curative options. We are developing novel biomaterials that mimic cartilage and bone to support regeneration, aiming to reverse OA through minimally invasive arthroscopic therapy. Our project will help define the target product profile, pre-clinical studies for FDA approval, and develop an insurance reimbursement strategy.
Learn more about Dr. Payne